Wire · opportunities
Ascletis Submits IND Application to the U.S. FDA for ASC30_39 FDC, a Potentially First-in ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 November 2026 · Fusion42 review
Ascletis has submitted an Investigational New Drug (IND) application to the U.S. FDA for ASC30_39 FDC, a novel oral fixed-dose combination therapy targeting obesity by combining a GLP-1 receptor agonist and a selective amylin receptor agonist.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 11 Nov 2026 and 17 Nov 2026.
◆ ◆ The Wire takeaway
Your obesity drug startup faces a higher bar as first-in-class oral therapies attract regulatory focus. Clarify FDA engagement paths now to speed clinical plans and seize market lead.
◆ Coverage
2 sources · first reported 11 Nov 2026 · latest 17 Nov 2026
◆ Related on Wire
◆ Topics